Skip to main content
. 2023 Feb 13;20(4):468–481. doi: 10.7150/ijms.78790

Figure 5.

Figure 5

miR-182-5p/PPARG regulates HaCaTs functionality (A) CCK8 assay of HaCaTs viability after treated with si-PPARG or miR-182-5p inhibitor plus si-PPARG. (B) Cell adhesion assay of HaCaTs after treated with si-PPARG or miR-182-5p inhibitor plus si-PPARG. (C) Extracellular adhesion matrix protein expression by ELISA of HaCaTs after treated with si-PPARG or miR-182-5p inhibitor plus si-PPARG. (D) Clone formation assay of HaCaTs after treated with si- PPARG or miR-182-5p inhibitor plus si-PPARG. (E) Would scratch assay of HaCaTs after treated with si-PPARG or miR-182-5p inhibitor plus si-PPARG. (F) Western blotting showed the expression of PPARG, MMP1, FN1 and GAPDH in HaCaTs after treated with si-PPARG or miR-182-5p inhibitor plus si-PPARG. All experiments were repeated independently for at least three times. Statistical evaluation was performed using one-way ANOVA. Mean ± SEM. *represents P < 0.05 compared with NC group. *P < 0.05, **P < 0.01, ***P < 0.001.